New anxiety drug shows promise in early trial

NCT ID NCT06653296

Completed Symptom relief Sponsor: Engrail Therapeutics INC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new drug called ENX-102 in 38 adults with generalized anxiety disorder. Participants received either a low, mid, or high dose of ENX-102 or a placebo for six weeks. The goal was to check safety and find the best dose. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ENX-102
What this could lead to: If successful, this could point toward a new treatment option for generalized anxiety disorder with a potentially better safety or tolerability profile.
What could go wrong: This is a small, early-phase trial with only 38 participants. The drug may not prove more effective than placebo, and side effects could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERAL ANXIETY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERAL ANXIETY DISORDER

Contacts and locations

Locations

MAC Clinical Research

Liverpool, UK, United Kingdom
MAC Clinical Research

Blackpool, United Kingdom
MAC Clinical Research

Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.